Welcome to our dedicated page for ZIMVIE news (Ticker: ZIMV), a resource for investors and traders seeking the latest updates and insights on ZIMVIE stock.
ZimVie Inc. reports developments in its dental implant and digital dentistry business, including product launches, distribution arrangements, operating results, and corporate governance matters. The company develops, manufactures, and delivers products and solutions for dental tooth replacement and restoration, including dental implants, biomaterials, and digital workflow tools.
Recurring updates include commercial expansion in international dental markets, launches of the RealGUIDE Software Suite and Implant Concierge service, and commercial arrangements that extend access to ZimVie implant systems. Company news also includes capital-structure disclosures, stockholder voting matters, material agreements, and clinical or regulatory disclosures tied to its dental products and technology portfolio.
ZimVie Inc. (Nasdaq: ZIMV) has released RealGUIDE® 5.4, an update to its dental implant software suite. This latest version introduces new features designed to enhance provider efficiency and cost savings. Key improvements include:
1. One-click nerve detection and automated bone and tooth segmentation for faster complex case planning and improved risk management.
2. New restorative design workflows to meet evolving clinic and dental laboratory needs.
3. Amplified CAD workflows for creating attractive implant dentistry designs.
4. Automated 'split-bar' toolset for efficient creation of complex multi-material prostheses.
5. Cloud-based design libraries for improved accessibility.
The update aims to make guided surgery the standard for all implant cases, potentially increasing implant dentistry adoption.
ZimVie Inc. (Nasdaq: ZIMV) has announced the U.S. launch of its GenTek® Genuine Restorative Components product portfolio, following FDA 510(k) clearance. This launch expands ZimVie's end-to-end prosthetic offerings in the dental market. The GenTek portfolio, first introduced in Europe in 2019, includes Ti-Bases, pre-milled abutment blanks, screws, instruments, and ancillary products for digitally driven CAD/CAM restorations.
Designed to mate with ZimVie implant systems, GenTek components ensure a perfect fit and tight seal for long-term aesthetic and functional restorations. The company anticipates strong demand in the U.S. market, following the product's success in Europe.
ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its second quarter 2024 financial results after market close on Thursday, August 1, 2024. The company management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested parties can register for the call online, with registration recommended more than 15 minutes before the call starts. A replay of the webcast will be available on the company's investor relations website.
On May 16, 2024, ZimVie, a global leader in the dental market, announced its participation in two upcoming investor conferences. The company will present at the Stifel 2024 Jaws & Paws Conference on May 30, 2024, at 11:30 a.m. Eastern Time, and at the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, at 3:20 p.m. Eastern Time. Interested parties can access a live webcast of these presentations through the 'Investors' section on ZimVie's website.
ZimVie Inc. (Nasdaq: ZIMV) reported third party net sales of $118.2 million, a net loss of ($11.5) million, and an adjusted EBITDA of $12.5 million for the first quarter of 2024. The company completed the sale of its spine business for $375 million, repaid $275 million of debt, and is now focusing on its dental market leadership.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.